Samer C - Search Results

1

Interaction between Fexofenadine and CYP Phenotyping Probe Drugs in Geneva Cocktail.

Bosilkovska M, Magliocco G, Desmeules J, Samer C, Daali Y. Bosilkovska M, et al. Among authors: samer c. J Pers Med. 2019 Oct 2;9(4):45. doi: 10.3390/jpm9040045. J Pers Med. 2019. PMID: 31581637 Free PMC article.

2

Management of chronic pain associated with temporomandibular disorders: a clinical practice guideline.

Busse JW, Casassus R, Carrasco-Labra A, Durham J, Mock D, Zakrzewska JM, Palmer C, Samer CF, Coen M, Guevremont B, Hoppe T, Guyatt GH, Crandon HN, Yao L, Sadeghirad B, Vandvik PO, Siemieniuk RAC, Lytvyn L, Hunskaar BS, Agoritsas T. Busse JW, et al. Among authors: samer cf. BMJ. 2023 Dec 15;383:e076227. doi: 10.1136/bmj-2023-076227. BMJ. 2023. PMID: 38101929

3

[Genetic polymorphism and drug interactions: their importance in the treatment of pain].

Samer CF, Piguet V, Dayer P, Desmeules JA. Samer CF, et al. Can J Anaesth. 2005 Oct;52(8):806-21. doi: 10.1007/BF03021775. Can J Anaesth. 2005. PMID: 16189332 Review. French.

4

Pharmacogenetics of analgesics: toward the individualization of prescription.

Rollason V, Samer C, Piguet V, Dayer P, Desmeules J. Rollason V, et al. Among authors: samer c. Pharmacogenomics. 2008 Jul;9(7):905-33. doi: 10.2217/14622416.9.7.905. Pharmacogenomics. 2008. PMID: 18597654 Review.

5

The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone.

Samer CF, Daali Y, Wagner M, Hopfgartner G, Eap CB, Rebsamen MC, Rossier MF, Hochstrasser D, Dayer P, Desmeules JA. Samer CF, et al. Br J Pharmacol. 2010 Jun;160(4):907-18. doi: 10.1111/j.1476-5381.2010.00673.x. Br J Pharmacol. 2010. PMID: 20590587 Free PMC article. Clinical Trial.

6

Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety.

Samer CF, Daali Y, Wagner M, Hopfgartner G, Eap CB, Rebsamen MC, Rossier MF, Hochstrasser D, Dayer P, Desmeules JA. Samer CF, et al. Br J Pharmacol. 2010 Jun;160(4):919-30. doi: 10.1111/j.1476-5381.2010.00709.x. Br J Pharmacol. 2010. PMID: 20590588 Free PMC article. Clinical Trial.

7

Automated system for on-line desorption of dried blood spots applied to LC/MS/MS pharmacokinetic study of flurbiprofen and its metabolite.

Déglon J, Thomas A, Daali Y, Lauer E, Samer C, Desmeules J, Dayer P, Mangin P, Staub C. Déglon J, et al. Among authors: samer c. J Pharm Biomed Anal. 2011 Jan 25;54(2):359-67. doi: 10.1016/j.jpba.2010.08.032. J Pharm Biomed Anal. 2011. PMID: 20864289

8

Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability.

Ancrenaz V, Daali Y, Fontana P, Besson M, Samer C, Dayer P, Desmeules J. Ancrenaz V, et al. Among authors: samer c. Curr Drug Metab. 2010 Oct;11(8):667-77. doi: 10.2174/138920010794233521. Curr Drug Metab. 2010. PMID: 20942779 Review.

9

Oral flurbiprofen metabolic ratio assessment using a single-point dried blood spot.

Daali Y, Samer C, Déglon J, Thomas A, Chabert J, Rebsamen M, Staub C, Dayer P, Desmeules J. Daali Y, et al. Among authors: samer c. Clin Pharmacol Ther. 2012 Mar;91(3):489-96. doi: 10.1038/clpt.2011.247. Epub 2012 Jan 11. Clin Pharmacol Ther. 2012. PMID: 22237256

10

Pharmacokinetic interaction between prasugrel and ritonavir in healthy volunteers.

Ancrenaz V, Déglon J, Samer C, Staub C, Dayer P, Daali Y, Desmeules J. Ancrenaz V, et al. Among authors: samer c. Basic Clin Pharmacol Toxicol. 2013 Feb;112(2):132-7. doi: 10.1111/j.1742-7843.2012.00932.x. Epub 2012 Oct 5. Basic Clin Pharmacol Toxicol. 2013. PMID: 22900583 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

109 results

Search Page